AI Clinical Trials: A Growing Trend with Unclear Boundaries

AI's footprint in clinical trials is expanding rapidly. If you're looking at the numbers, the increase is undeniable. From North America to Europe, references to machine learning, deep learning, chatbots, GPTs, and large language models in clinical trials are becoming commonplace.

Geographical Trends

China and the United States are at the forefront, contributing the largest number of AI-related trials. Notably, countries like Italy, France, Spain, the UK, and Turkey are catching up. It's not just about numbers. it's about where these innovations are taking root. The reality is, these countries are investing heavily in integrating AI into healthcare.

The Hybrid Approach

Here's where it gets interesting. A new study explored a hybrid approach, using a new AI model, GPT-5.5, alongside human review. The goal? To screen and categorize clinical trial records with an AI focus. This method proved effective in some areas, like spotting trials not substantially involving AI. However, it struggled with more nuanced classifications, especially in human-AI interaction.

Why does this matter? Well, if AI can't yet clearly define human interactions in these trials, how can we trust it to enhance our healthcare systems? This raises a important question: Are we moving too fast without enough clarity?

The Need for Better Reporting

The study suggests that while hybrid human-AI screening could work, it needs clearer reporting standards. Vague descriptions of human-AI interactions make classification tricky. In healthcare, where precision is everything, this is a significant gap.

Strip away the marketing and you get a process that's promising but not quite there yet. For AI to truly revolutionize clinical trials, clearer definitions and transparency in trial reporting are non-negotiable.